|
WO2011002988A1
(en)
|
2009-07-01 |
2011-01-06 |
Transposagen Biopharmaceuticals, Inc. |
Genetically modified rat models for severe combined immunodeficiency (scid)
|
|
EA201391373A1
(ru)
|
2011-03-23 |
2014-07-30 |
Пайонир Хай-Бред Интернэшнл, Инк. |
Способы получения сложного локуса трансгенных признаков
|
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
EP2847335B1
(en)
|
2012-04-25 |
2018-06-27 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
|
NZ714353A
(en)
|
2012-05-25 |
2017-05-26 |
Univ California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
JP6225182B2
(ja)
|
2012-07-11 |
2017-11-01 |
サンガモ セラピューティクス， インコーポレイテッド |
リソソーム貯蔵疾患の処置のための方法および組成物
|
|
CN105188767A
(zh)
*
|
2012-07-25 |
2015-12-23 |
布罗德研究所有限公司 |
可诱导的dna结合蛋白和基因组干扰工具及其应用
|
|
DE202013012597U1
(de)
|
2012-10-23 |
2017-11-21 |
Toolgen, Inc. |
Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung
|
|
AU2013355214B2
(en)
|
2012-12-06 |
2017-06-15 |
Sigma-Aldrich Co. Llc |
Crispr-based genome modification and regulation
|
|
PL2931898T3
(pl)
|
2012-12-12 |
2016-09-30 |
Le Cong |
Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
SG11201504523UA
(en)
|
2012-12-12 |
2015-07-30 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
EP2898075B1
(en)
*
|
2012-12-12 |
2016-03-09 |
The Broad Institute, Inc. |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
EP2940140B1
(en)
|
2012-12-12 |
2019-03-27 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
|
EP4286403A3
(en)
|
2012-12-12 |
2024-02-14 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
KR20220139433A
(ko)
|
2012-12-17 |
2022-10-14 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Rna-가이드된 인간 게놈 조작
|
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
SG10201706741VA
(en)
|
2013-02-20 |
2017-10-30 |
Regeneron Pharma |
Genetic modification of rats
|
|
CA2905432C
(en)
*
|
2013-03-14 |
2021-09-14 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
EP2970208A4
(en)
|
2013-03-15 |
2016-11-30 |
Gen Hospital Corp |
SPECIFICITY INCREASES FOR RNA-MEDIATED CHANGES
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
CN105518146B
(zh)
|
2013-04-04 |
2022-07-15 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
|
BR112015026197B1
(pt)
|
2013-04-16 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc |
Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente
|
|
WO2014172470A2
(en)
*
|
2013-04-16 |
2014-10-23 |
Whitehead Institute For Biomedical Research |
Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
|
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
|
EP3004339B1
(en)
*
|
2013-05-29 |
2021-07-07 |
Cellectis |
New compact scaffold of cas9 in the type ii crispr system
|
|
WO2014194190A1
(en)
*
|
2013-05-30 |
2014-12-04 |
The Penn State Research Foundation |
Gene targeting and genetic modification of plants via rna-guided genome editing
|
|
EP3011029B1
(en)
|
2013-06-17 |
2019-12-11 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
JP6665088B2
(ja)
|
2013-06-17 |
2020-03-13 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
|
|
EP3011031B1
(en)
|
2013-06-17 |
2020-09-30 |
The Broad Institute Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
WO2014204729A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
WO2015006498A2
(en)
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
SG11201600060VA
(en)
*
|
2013-07-10 |
2016-02-26 |
Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
|
US11306328B2
(en)
*
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
CA2922089C
(en)
|
2013-08-22 |
2022-07-05 |
E. I. Du Pont De Nemours And Company |
Plant genome modification using guide rna/cas endonuclease systems and methods of use
|
|
KR20160060659A
(ko)
|
2013-08-29 |
2016-05-30 |
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
CN105637087A
(zh)
|
2013-09-18 |
2016-06-01 |
科马布有限公司 |
方法、细胞与生物体
|
|
WO2015054507A1
(en)
|
2013-10-10 |
2015-04-16 |
Pronutria, Inc. |
Nutritive polypeptide production systems, and methods of manufacture and use thereof
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
EP4372090A3
(en)
|
2013-11-07 |
2024-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
|
EP3375877A1
(en)
*
|
2013-11-18 |
2018-09-19 |
Crispr Therapeutics AG |
Crispr-cas system materials and methods
|
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
|
KR102170502B1
(ko)
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
게놈의 표적화된 변형을 위한 방법 및 조성물
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
BR112016013547A2
(pt)
|
2013-12-12 |
2017-10-03 |
Broad Inst Inc |
Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
|
|
EP3080261B1
(en)
|
2013-12-12 |
2019-05-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP4219699A1
(en)
|
2013-12-12 |
2023-08-02 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
BR112016013213A2
(pt)
|
2013-12-12 |
2017-12-05 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
|
|
KR20160097327A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
|
|
EP3079725B1
(en)
*
|
2013-12-12 |
2019-10-16 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
SG11201604815RA
(en)
|
2013-12-19 |
2016-07-28 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
RS60492B1
(sr)
|
2014-02-11 |
2020-08-31 |
Univ Colorado Regents |
Multipleksirani genomski inženjering omogućen pomoću crispr
|
|
KR20160130392A
(ko)
|
2014-02-18 |
2016-11-11 |
듀크 유니버시티 |
바이러스 복제의 불활성화를 위한 조성물 및 그의 제조 및 사용 방법
|
|
EP3110945B1
(en)
|
2014-02-27 |
2021-09-08 |
Monsanto Technology LLC |
Compositions and methods for site directed genomic modification
|
|
CN106817904A
(zh)
|
2014-02-27 |
2017-06-09 |
博德研究所 |
T细胞平衡基因表达、物质组合物及其使用方法
|
|
US11028388B2
(en)
|
2014-03-05 |
2021-06-08 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
DK3116997T3
(da)
|
2014-03-10 |
2019-08-19 |
Editas Medicine Inc |
Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
|
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
|
WO2015153789A1
(en)
*
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
|
WO2015153780A1
(en)
|
2014-04-02 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
EP3556858A3
(en)
|
2014-04-09 |
2020-01-22 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
AU2015247323B2
(en)
*
|
2014-04-18 |
2021-07-01 |
Editas Medicine, Inc. |
CRISPR-Cas-related methods, compositions and components for cancer immunotherapy
|
|
EP3149171A1
(en)
|
2014-05-30 |
2017-04-05 |
The Board of Trustees of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
|
ES3019688T3
(en)
|
2014-06-06 |
2025-05-21 |
Regeneron Pharma |
Methods and compositions for modifying a targeted locus
|
|
WO2015192020A1
(en)
|
2014-06-13 |
2015-12-17 |
Children's Medical Center Corporation |
Products and methods to isolate mitochondria
|
|
KR102425438B1
(ko)
|
2014-06-23 |
2022-07-27 |
더 제너럴 하스피탈 코포레이션 |
서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq)
|
|
RU2771532C2
(ru)
|
2014-06-26 |
2022-05-05 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленных генетических модификаций и способы их применения
|
|
BR112017000482A2
(pt)
|
2014-07-11 |
2017-11-07 |
Du Pont |
métodos para produzir uma planta mutante e para gerar uma planta, planta, semente, rna, métodos para produzir uma célula, para duplicar um fragmento gênico, para substituir uma primeira sequência promotora, para inserir um elemento regulador em uma sequência de nucleotídeos e para inserir um íntron em uma sequência de nucleotídeos, planta de milho e célula vegetal
|
|
ES2965286T3
(es)
*
|
2014-07-14 |
2024-04-12 |
Univ Washington State |
Silenciamiento de NANOS que abate las células germinales
|
|
CN104152414B
(zh)
*
|
2014-07-18 |
2018-03-13 |
中国科学院广州生物医药与健康研究院 |
对细胞基因组的预定位点进行基因改造的方法
|
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
KR101817482B1
(ko)
*
|
2014-08-06 |
2018-02-22 |
주식회사 툴젠 |
캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
|
|
EP3180034B1
(en)
*
|
2014-08-11 |
2022-04-20 |
The Board of Regents of The University of Texas System |
Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2780904T3
(es)
|
2014-08-17 |
2020-08-27 |
Broad Inst Inc |
Edición genómica usando nickasas Cas9
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
AU2015308910B2
(en)
|
2014-08-27 |
2017-12-07 |
Caribou Biosciences, Inc. |
Methods for increasing Cas9-mediated engineering efficiency
|
|
EP3188763B1
(en)
|
2014-09-02 |
2020-05-13 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification
|
|
WO2016040030A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
|
EA201790624A1
(ru)
|
2014-09-17 |
2017-08-31 |
Новартис Аг |
Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
US10040048B1
(en)
|
2014-09-25 |
2018-08-07 |
Synthego Corporation |
Automated modular system and method for production of biopolymers
|
|
CN104546931B
(zh)
*
|
2014-09-30 |
2019-04-09 |
深圳华大基因科技有限公司 |
华德萨特氏菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
|
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
|
US20180250424A1
(en)
|
2014-10-10 |
2018-09-06 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
US10583201B2
(en)
*
|
2014-10-10 |
2020-03-10 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
WO2016069591A2
(en)
|
2014-10-27 |
2016-05-06 |
The Broad Institute Inc. |
Compositions, methods and use of synthetic lethal screening
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
EP4464338A3
(en)
|
2014-11-07 |
2025-02-12 |
Editas Medicine, Inc. |
Systems for improving crispr/cas-mediated genome-editing
|
|
US10858662B2
(en)
|
2014-11-19 |
2020-12-08 |
Institute For Basic Science |
Genome editing with split Cas9 expressed from two vectors
|
|
US10362771B2
(en)
|
2014-11-20 |
2019-07-30 |
Kyoto University |
Method for knock-in of DNA into target region of mammalian genome, and cell
|
|
CN113444747B
(zh)
|
2014-11-21 |
2025-02-11 |
瑞泽恩制药公司 |
使用成对向导rna进行靶向遗传修饰的方法和组合物
|
|
US11168369B2
(en)
|
2014-11-25 |
2021-11-09 |
The Brigham And Women's Hospital, Inc. |
Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
|
|
EP3224362B1
(en)
|
2014-11-26 |
2024-09-25 |
The Regents of The University of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
KR102763527B1
(ko)
|
2014-12-03 |
2025-02-05 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
|
US9888673B2
(en)
|
2014-12-10 |
2018-02-13 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
WO2016094880A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
CN107208096B
(zh)
*
|
2014-12-18 |
2021-02-12 |
综合基因技术公司 |
基于crispr的组合物和使用方法
|
|
CN107208113A
(zh)
|
2014-12-19 |
2017-09-26 |
瑞泽恩制药公司 |
用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
|
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
PL3193901T3
(pl)
|
2014-12-23 |
2018-10-31 |
4D Pharma Research Limited |
Polipeptyd pyrynowy i immunomodulacja
|
|
WO2016106121A1
(en)
|
2014-12-23 |
2016-06-30 |
Syngenta Participations Ag |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
ES2658310T3
(es)
|
2014-12-23 |
2018-03-09 |
4D Pharma Research Limited |
Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
JP6835726B2
(ja)
|
2015-01-28 |
2021-02-24 |
パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド |
Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法
|
|
US20180245073A1
(en)
*
|
2015-02-23 |
2018-08-30 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
WO2016138488A2
(en)
|
2015-02-26 |
2016-09-01 |
The Broad Institute Inc. |
T cell balance gene expression, compositions of matters and methods of use thereof
|
|
US11261466B2
(en)
|
2015-03-02 |
2022-03-01 |
Sinai Health System |
Homologous recombination factors
|
|
CN107532161A
(zh)
|
2015-03-03 |
2018-01-02 |
通用医疗公司 |
具有改变的PAM特异性的工程化CRISPR‑Cas9核酸酶
|
|
WO2016160389A1
(en)
|
2015-03-27 |
2016-10-06 |
E I Du Pont De Nemours And Company |
Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants
|
|
WO2016161380A1
(en)
*
|
2015-04-01 |
2016-10-06 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
|
JP6873911B2
(ja)
*
|
2015-04-06 |
2021-05-19 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP4019975A1
(en)
|
2015-04-24 |
2022-06-29 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
|
HK1254190A1
(zh)
|
2015-05-08 |
2019-07-12 |
President And Fellows Of Harvard College |
通用供体干细胞和相关方法
|
|
JP7030522B2
(ja)
|
2015-05-11 |
2022-03-07 |
エディタス・メディシン、インコーポレイテッド |
幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
|
|
WO2016183438A1
(en)
*
|
2015-05-14 |
2016-11-17 |
Massachusetts Institute Of Technology |
Self-targeting genome editing system
|
|
CN107709562A
(zh)
*
|
2015-05-15 |
2018-02-16 |
先锋国际良种公司 |
指导rna/cas内切核酸酶系统
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
JP2018516597A
(ja)
*
|
2015-05-29 |
2018-06-28 |
アジェノビア コーポレーション |
移植のために細胞を処置する方法および組成物
|
|
EA037359B1
(ru)
|
2015-06-01 |
2021-03-17 |
Тэмпл Юниверсити - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
|
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
|
EP3303585A4
(en)
|
2015-06-03 |
2018-10-31 |
Board of Regents of the University of Nebraska |
Dna editing using single-stranded dna
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
JP7396783B2
(ja)
|
2015-06-09 |
2023-12-12 |
エディタス・メディシン、インコーポレイテッド |
移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物
|
|
PE20180243A1
(es)
|
2015-06-15 |
2018-01-31 |
4D Pharma Res Ltd |
Composiciones que comprenden cepas bacterianas
|
|
CN114984057A
(zh)
|
2015-06-15 |
2022-09-02 |
4D制药研究有限公司 |
包含细菌菌株的组合物
|
|
MA41060B1
(fr)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
HUE058252T2
(hu)
|
2015-06-15 |
2022-07-28 |
4D Pharma Res Ltd |
Baktériumtörzseket tartalmazó készítmények
|
|
MA41010B1
(fr)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
EP3310931B1
(en)
|
2015-06-17 |
2021-11-17 |
The UAB Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
|
JP2018518182A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体
|
|
FI3430134T3
(fi)
|
2015-06-18 |
2023-01-13 |
|
Uusia CRISPR-entsyymejä ja järjestelmiä
|
|
RU2752834C2
(ru)
*
|
2015-06-18 |
2021-08-09 |
Те Брод Инститьют, Инк. |
Мутации фермента crispr, уменьшающие нецелевые эффекты
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
JP2018519811A
(ja)
|
2015-06-29 |
2018-07-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用
|
|
US20170000743A1
(en)
*
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
US10456452B2
(en)
|
2015-07-02 |
2019-10-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
|
|
GB2595063B
(en)
|
2015-07-31 |
2022-03-09 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
US9580727B1
(en)
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP4512819A3
(en)
|
2015-08-12 |
2025-08-06 |
The General Hospital Corporation |
Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
|
|
EP3334746B1
(en)
|
2015-08-14 |
2021-11-24 |
The University Of Sydney |
Connexin 45 inhibition for therapy
|
|
EP3337908A4
(en)
|
2015-08-18 |
2019-01-23 |
The Broad Institute, Inc. |
METHOD AND COMPOSITIONS FOR CHANGING THE FUNCTION AND STRUCTURE OF CHROMATIN GRINDING AND / OR DOMAINS
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
HK1257676A1
(zh)
|
2015-08-28 |
2019-10-25 |
The General Hospital Corporation |
工程化 crispr-cas 9 核酸酶
|
|
IL241462A0
(en)
|
2015-09-10 |
2015-11-30 |
Yeda Res & Dev |
Heterologous engineering of betalain pigments in plants
|
|
EP3347467B1
(en)
|
2015-09-11 |
2021-06-23 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
US20170088828A1
(en)
*
|
2015-09-29 |
2017-03-30 |
Agenovir Corporation |
Compositions and methods for treatment of latent viral infections
|
|
KR20180053748A
(ko)
|
2015-09-30 |
2018-05-23 |
더 제너럴 하스피탈 코포레이션 |
시퀀싱(circle-seq)에 의한 절단 반응의 포괄적인 시험관내 보고
|
|
WO2017059241A1
(en)
|
2015-10-02 |
2017-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3365441A1
(en)
|
2015-10-22 |
2018-08-29 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
|
ES2699848T3
(es)
|
2015-10-23 |
2019-02-13 |
Caribou Biosciences Inc |
Acido nucleico CRISPR clase 2 de tipo cruzado modificado que se dirige a ácidos nucleicos
|
|
US12043852B2
(en)
|
2015-10-23 |
2024-07-23 |
President And Fellows Of Harvard College |
Evolved Cas9 proteins for gene editing
|
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075265A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute, Inc. |
Multiplex analysis of single cell constituents
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075294A1
(en)
|
2015-10-28 |
2017-05-04 |
The Board Institute Inc. |
Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017083852A1
(en)
|
2015-11-13 |
2017-05-18 |
MOORE, Tara |
Methods for the treatment of corneal dystrophies
|
|
US12282014B2
(en)
|
2015-11-19 |
2025-04-22 |
Dana-Farber Cancer Institute, Inc. |
Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
|
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
|
EP3363446A1
(en)
|
2015-11-20 |
2018-08-22 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
|
EP3380613B1
(en)
*
|
2015-11-23 |
2022-10-26 |
The Regents of the University of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
|
EP4620519A3
(en)
|
2015-11-30 |
2025-10-22 |
Sana Biotechnology, Inc. |
Methods and compositions relating to chondrisomes from blood products
|
|
WO2017095960A1
(en)
*
|
2015-11-30 |
2017-06-08 |
Synthetic Genomics, Inc. |
Compositions and methods for expressing genes in algae
|
|
WO2017093370A1
(en)
*
|
2015-12-03 |
2017-06-08 |
Technische Universität München |
T-cell specific genome editing
|
|
WO2017096328A1
(en)
|
2015-12-04 |
2017-06-08 |
Caribou Biosciences, Inc. |
Engineered nucleic-acid targeting nucleic acids
|
|
US11293029B2
(en)
|
2015-12-07 |
2022-04-05 |
Zymergen Inc. |
Promoters from Corynebacterium glutamicum
|
|
US11208649B2
(en)
|
2015-12-07 |
2021-12-28 |
Zymergen Inc. |
HTP genomic engineering platform
|
|
US9988624B2
(en)
|
2015-12-07 |
2018-06-05 |
Zymergen Inc. |
Microbial strain improvement by a HTP genomic engineering platform
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
WO2017114497A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
US11672866B2
(en)
|
2016-01-08 |
2023-06-13 |
Paul N. DURFEE |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
|
EA201891619A1
(ru)
|
2016-01-11 |
2019-02-28 |
Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити |
Химерные белки и способы регулирования экспрессии генов
|
|
MY194127A
(en)
|
2016-01-11 |
2022-11-14 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of immunotherapy
|
|
CA3011472A1
(en)
|
2016-01-15 |
2017-07-20 |
The Children's Medical Center Corporation |
Therapeutic use of mitochondria and combined mitochondrial agents for transplantation
|
|
WO2017139309A1
(en)
|
2016-02-12 |
2017-08-17 |
Ceres, Inc. |
Methods and materials for high throughput testing of mutagenized allele combinations
|
|
WO2017143071A1
(en)
|
2016-02-18 |
2017-08-24 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
WO2017147196A1
(en)
|
2016-02-22 |
2017-08-31 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating immune phenotypes
|
|
CN105543196A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VRER及其编码基因与应用
|
|
CN105543195A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VQR及其编码基因与应用
|
|
CA3016571A1
(en)
|
2016-03-04 |
2017-09-08 |
Indoor Biotechnologies Inc. |
Fel d 1 knockouts and associated compositions and methods based on crispr-cas9 genomic editing
|
|
SG10201913557TA
(en)
|
2016-03-04 |
2020-02-27 |
4D Pharma Plc |
Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
|
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
|
WO2017161043A1
(en)
|
2016-03-16 |
2017-09-21 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
WO2017161325A1
(en)
|
2016-03-17 |
2017-09-21 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
US20200291370A1
(en)
*
|
2016-03-18 |
2020-09-17 |
President And Fellows Of Harvard College |
Mutant Cas Proteins
|
|
WO2017165859A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
EP3433364A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
EP4047092B1
(en)
|
2016-04-13 |
2025-07-30 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
|
WO2017181119A2
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
WO2017189308A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
AU2017253089B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN107304435A
(zh)
*
|
2016-04-22 |
2017-10-31 |
中国科学院青岛生物能源与过程研究所 |
一种Cas9/RNA系统及其应用
|
|
US11213594B2
(en)
|
2016-04-29 |
2022-01-04 |
Poseida Therapeutics, Inc. |
Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
AU2017283713B2
(en)
|
2016-06-17 |
2021-04-08 |
Massachusetts Institute Of Technology |
Type VI CRISPR orthologs and systems
|
|
AU2017280353B2
(en)
|
2016-06-24 |
2021-11-11 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
US11471462B2
(en)
|
2016-06-27 |
2022-10-18 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
EP3478845A4
(en)
|
2016-06-30 |
2019-07-31 |
Zymergen, Inc. |
METHOD OF GENERATING A GLUCOSE PERMEASE LIBRARY AND USES THEREOF
|
|
WO2018005655A2
(en)
|
2016-06-30 |
2018-01-04 |
Zymergen Inc. |
Methods for generating a bacterial hemoglobin library and uses thereof
|
|
TWI802545B
(zh)
|
2016-07-13 |
2023-05-21 |
英商４Ｄ製藥有限公司 |
包含細菌菌株之組合物
|
|
ES2938210T3
(es)
|
2016-07-13 |
2023-04-05 |
Vertex Pharma |
Métodos, composiciones y kits para aumentar la eficiencia de edición del genoma
|
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
|
US11566263B2
(en)
|
2016-08-02 |
2023-01-31 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290 associated disease
|
|
CA3032699A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
RU2767206C2
(ru)
*
|
2016-08-12 |
2022-03-16 |
Тулджен Инкорпорейтед |
Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента
|
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
WO2018035250A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
|
JP7050215B2
(ja)
*
|
2016-08-19 |
2022-04-08 |
ツールゲン インコーポレイテッド |
人工的に操作された血管新生調節系
|
|
WO2020225754A1
(en)
|
2019-05-06 |
2020-11-12 |
Mcmullen Tara |
Crispr gene editing for autosomal dominant diseases
|
|
KR20230155013A
(ko)
|
2016-08-20 |
2023-11-09 |
아벨리노 랩 유에스에이, 인크. |
단일 가이드 RNA, CRISPR/Cas9 시스템, 및 이의 사용방법
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
EP3510145A4
(en)
|
2016-09-06 |
2020-03-25 |
The Children's Medical Center Corporation |
IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
EP4431607A3
(en)
|
2016-09-09 |
2024-12-11 |
The Board of Trustees of the Leland Stanford Junior University |
High-throughput precision genome editing
|
|
IL247752A0
(en)
|
2016-09-11 |
2016-11-30 |
Yeda Res & Dev |
Compositions and methods for modulating gene expression for site-directed mutagenesis
|
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
|
WO2018064387A1
(en)
|
2016-09-28 |
2018-04-05 |
Novartis Ag |
Porous membrane-based macromolecule delivery system
|
|
WO2018064208A1
(en)
|
2016-09-28 |
2018-04-05 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
EP3523426A4
(en)
|
2016-09-30 |
2020-01-22 |
The Regents of The University of California |
RNA GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
US11306324B2
(en)
*
|
2016-10-14 |
2022-04-19 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
|
GB2604416B
(en)
|
2016-10-18 |
2023-03-15 |
Univ Minnesota |
Tumor infiltating lymphocytes and methods of therapy
|
|
WO2018078131A1
(en)
*
|
2016-10-28 |
2018-05-03 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
CA3042259A1
(en)
|
2016-11-04 |
2018-05-11 |
Flagship Pioneering Innovations V. Inc. |
Novel plant cells, plants, and seeds
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
US9816093B1
(en)
|
2016-12-06 |
2017-11-14 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
|
WO2018107103A1
(en)
|
2016-12-09 |
2018-06-14 |
The Broad Institute, Inc. |
Crispr-systems for modifying a trait of interest in a plant
|
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
|
US11674128B2
(en)
*
|
2016-12-12 |
2023-06-13 |
Tsinghua University |
Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
|
|
KR20210035022A
(ko)
|
2016-12-14 |
2021-03-31 |
리간달 인코포레이티드 |
핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법
|
|
US12286727B2
(en)
|
2016-12-19 |
2025-04-29 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
BR112019012819A2
(pt)
|
2016-12-22 |
2019-11-26 |
Monsanto Technology Llc |
manipulação de cultura com base em edição de genoma e produção de plantas braquíticas
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
|
EP3565907B1
(en)
|
2017-01-06 |
2022-05-04 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
US11873496B2
(en)
|
2017-01-09 |
2024-01-16 |
Whitehead Institute For Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
SG11201906795SA
(en)
|
2017-01-28 |
2019-08-27 |
Inari Agriculture Inc |
Novel plant cells, plants, and seeds
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
WO2018148511A1
(en)
|
2017-02-10 |
2018-08-16 |
Zymergen Inc. |
A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018160865A1
(en)
|
2017-03-01 |
2018-09-07 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
|
JP2020508685A
(ja)
|
2017-03-03 |
2020-03-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
サプレッサーｔＲＮＡ及びデアミナーゼによる変異のＲＮＡターゲティング
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
KR102454284B1
(ko)
|
2017-03-15 |
2022-10-12 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규 cas13b 오르소로그 crispr 효소 및 시스템
|
|
WO2018170515A1
(en)
|
2017-03-17 |
2018-09-20 |
The Broad Institute, Inc. |
Methods for identifying and modulating co-occurant cellular phenotypes
|
|
EP3601562A1
(en)
|
2017-03-23 |
2020-02-05 |
President and Fellows of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018175924A1
(en)
|
2017-03-24 |
2018-09-27 |
The Broad Institute, Inc. |
Methods and compositions for regulating innate lymphoid cell inflammatory responses
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
BR112019021378A2
(pt)
|
2017-04-12 |
2020-05-05 |
Massachusetts Inst Technology |
ortólogos de crispr tipo vi inovadores e sistemas
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
|
US12350368B2
(en)
|
2017-04-14 |
2025-07-08 |
The Broad Institute, Inc. |
Delivery of large payloads
|
|
WO2018195019A1
(en)
|
2017-04-18 |
2018-10-25 |
The Broad Institute Inc. |
Compositions for detecting secretion and methods of use
|
|
SG11201909797QA
(en)
|
2017-04-20 |
2019-11-28 |
Egenesis Inc |
Methods for generating genetically modified animals
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
EP3615672A1
(en)
|
2017-04-28 |
2020-03-04 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
KR102338993B1
(ko)
*
|
2017-05-08 |
2021-12-14 |
주식회사 툴젠 |
인위적으로 조작된 조작면역세포
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
CA3062595A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
WO2018213351A1
(en)
*
|
2017-05-16 |
2018-11-22 |
The Regents Of The University Of California |
Thermostable rna-guided endonucleases and methods of use thereof
|
|
EP3625343B1
(en)
|
2017-05-18 |
2025-09-10 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
MA48941A
(fr)
|
2017-05-22 |
2020-04-08 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
TW201907931A
(zh)
|
2017-05-24 |
2019-03-01 |
英商4D製藥研究有限公司 |
包含細菌菌株之組合物
|
|
AU2018273986A1
(en)
|
2017-05-25 |
2019-12-12 |
The General Hospital Corporation |
Bipartite base editor (BBE) architectures and type-II-C-Cas9 zinc finger editing
|
|
WO2018217981A1
(en)
|
2017-05-26 |
2018-11-29 |
North Carolina State University |
Altered guide rnas for modulating cas9 activity and methods of use
|
|
EP3409104A1
(en)
|
2017-05-31 |
2018-12-05 |
Vilmorin et Cie |
Tomato plant resistant to tomato yellow leaf curl virus, powdery mildew, and nematodes
|
|
EP3409106A1
(en)
|
2017-06-01 |
2018-12-05 |
Vilmorin et Cie |
Tolerance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus (tbrfv)
|
|
WO2020249996A1
(en)
|
2019-06-14 |
2020-12-17 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus
|
|
WO2018226602A1
(en)
|
2017-06-05 |
2018-12-13 |
Research Institute At Nationwide Children's Hospital |
Enhanced modified viral capsid proteins
|
|
CA3102054A1
(en)
|
2017-06-05 |
2018-12-13 |
Fred Hutchinson Cancer Research Center |
Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
|
|
WO2018226900A2
(en)
|
2017-06-06 |
2018-12-13 |
Zymergen Inc. |
A htp genomic engineering platform for improving fungal strains
|
|
ES2875579T3
(es)
|
2017-06-06 |
2021-11-10 |
Zymergen Inc |
Plataforma de ingeniería genómica de HTP para mejorar Escherichia coli
|
|
AU2018279112B2
(en)
*
|
2017-06-07 |
2024-11-07 |
Arc Bio, Llc |
Creation and use of guide nucleic acids
|
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
KR20250028508A
(ko)
|
2017-06-13 |
2025-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
큐론을 포함하는 조성물 및 그의 용도
|
|
AU2018283155B2
(en)
|
2017-06-14 |
2024-11-28 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleoprotein complexes and methods of use
|
|
SMT202200272T1
(it)
|
2017-06-14 |
2022-07-21 |
4D Pharma Res Limited |
Composizioni comprendenti ceppi batterici
|
|
BR112019026477A2
(pt)
|
2017-06-14 |
2020-07-14 |
4D Pharma Research Limited |
composições compreendendo cepas bacterianas
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
RS61210B1
(sr)
|
2017-06-14 |
2021-01-29 |
4D Pharma Res Ltd |
Kompozicije koje sadrže bakterijske sojeve
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
CA3064601A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス，インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
|
WO2019003193A1
(en)
|
2017-06-30 |
2019-01-03 |
Novartis Ag |
METHODS FOR TREATING DISEASES USING GENE EDITING SYSTEMS
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
WO2019018440A1
(en)
|
2017-07-17 |
2019-01-24 |
The Broad Institute, Inc. |
HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
|
|
WO2019018551A2
(en)
|
2017-07-18 |
2019-01-24 |
Lee Tzumin |
METHODS AND COMPOSITIONS FOR GENETICALLY GENETIC HANDLING OF GENES AND CELLS
|
|
WO2019018694A1
(en)
|
2017-07-19 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
DIAGNOSIS AND TREATMENT OF CANCER
|
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
|
|
EP4445954A3
(en)
|
2017-07-31 |
2025-01-08 |
Reflection Biotechnologies Limited |
Cellular models of and therapies for ocular diseases
|
|
WO2019040650A1
(en)
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
|
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
|
US11713452B2
(en)
|
2017-09-08 |
2023-08-01 |
University Of North Texas Health Science Center |
Engineered CAS9 variants
|
|
US20190076814A1
(en)
|
2017-09-11 |
2019-03-14 |
Synthego Corporation |
Biopolymer synthesis system and method
|
|
BR112020005361A2
(pt)
|
2017-09-19 |
2020-09-24 |
The University Of British Columbia |
anticorpos anti-hla-a2 e métodos de uso dos mesmos
|
|
IT201700105372A1
(it)
*
|
2017-09-20 |
2019-03-20 |
Fondazione St Italiano Tecnologia |
Molecola di acido nucleico funzionale e relativo uso
|
|
CA3076547A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
Novel anti-hla-a2 antibodies and uses thereof
|
|
CA3076249A1
(en)
|
2017-09-21 |
2019-03-28 |
Dana-Farber Cancer Institute, Inc. |
Isolation, preservation, compositions and uses of extracts from justicia plants
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
AU2018335571B2
(en)
|
2017-09-25 |
2025-05-08 |
Agrospheres, Inc. |
Compositions and methods for scalable production and delivery of biologicals
|
|
US10933027B1
(en)
|
2017-09-25 |
2021-03-02 |
National Technology & Engineering Solutions Of Sandia, Llc |
Expanded pore particles and delivery methods thereof
|
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
PROCEDURES AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANT GENE SIGNATURE IN CANCER
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
|
JP2021500036A
(ja)
|
2017-10-16 |
2021-01-07 |
ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. |
アデノシン塩基編集因子の使用
|
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
|
WO2019079772A1
(en)
|
2017-10-20 |
2019-04-25 |
Fred Hutchinson Cancer Research Center |
SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
|
WO2019094984A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
|
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3710583A1
(en)
|
2017-11-16 |
2020-09-23 |
Astrazeneca AB |
Compositions and methods for improving the efficacy of cas9-based knock-in strategies
|
|
CR20200251A
(es)
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
US11332736B2
(en)
|
2017-12-07 |
2022-05-17 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
|
CN109912702B
(zh)
*
|
2017-12-13 |
2021-03-16 |
中国科学院遗传与发育生物学研究所 |
蛋白质OsARE1在调控植物抗低氮性中的应用
|
|
WO2019118935A1
(en)
|
2017-12-14 |
2019-06-20 |
Casebia Therapeutics Limited Liability Partnership |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
EP3728575A4
(en)
|
2017-12-22 |
2021-11-24 |
The Broad Institute, Inc. |
CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF DNA BASES
|
|
US20190201548A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for engineering erythroid cells
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
EP3737690A1
(en)
|
2018-01-12 |
2020-11-18 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
|
US12005127B2
(en)
|
2018-01-17 |
2024-06-11 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
JP7483612B2
(ja)
|
2018-01-17 |
2024-05-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット
|
|
WO2019143675A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
|
EP3746124A4
(en)
|
2018-01-30 |
2021-10-27 |
Foghorn Therapeutics Inc. |
COMPOUNDS AND THEIR USES
|
|
JP2021512617A
(ja)
|
2018-02-08 |
2021-05-20 |
ザイマージェン インコーポレイテッド |
ＣｏｒｙｎｅｂａｃｔｅｒｉｕｍにおいてＣＲＩＳＰＲを使用するゲノム編集
|
|
WO2019165168A1
(en)
|
2018-02-23 |
2019-08-29 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
SG11202008956XA
(en)
|
2018-03-14 |
2020-10-29 |
Editas Medicine Inc |
Systems and methods for the treatment of hemoglobinopathies
|
|
CN112424348B
(zh)
|
2018-03-19 |
2024-12-31 |
克里斯珀医疗股份公司 |
新颖的rna-可编程的内切核酸酶系统及其用途
|
|
CA3096274A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
US11981739B2
(en)
|
2018-04-13 |
2024-05-14 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
US11898203B2
(en)
|
2018-04-17 |
2024-02-13 |
The General Hospital Corporation |
Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents
|
|
WO2019204585A1
(en)
|
2018-04-19 |
2019-10-24 |
Massachusetts Institute Of Technology |
Single-stranded break detection in double-stranded dna
|
|
MX2020010974A
(es)
|
2018-04-19 |
2021-01-20 |
Univ California |
Composiciones y métodos para la edición de genes.
|
|
ES2922902T3
(es)
|
2018-04-24 |
2022-09-21 |
Kws Saat Se & Co Kgaa |
Plantas con digestibilidad mejorada y haplotipos marcadores
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
IL314291A
(en)
|
2018-04-27 |
2024-09-01 |
Genedit Inc |
Cationic polymer and use for biomolecule delivery
|
|
WO2019210268A2
(en)
|
2018-04-27 |
2019-10-31 |
The Broad Institute, Inc. |
Sequencing-based proteomics
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3784254A1
(en)
|
2018-04-27 |
2021-03-03 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019213660A2
(en)
|
2018-05-04 |
2019-11-07 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
|
AU2019265916A1
(en)
|
2018-05-10 |
2020-12-10 |
Auxolytic Ltd |
Gene therapy methods and compositions using auxotrophic regulatable cells
|
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12227776B2
(en)
|
2018-06-13 |
2025-02-18 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US11045554B1
(en)
|
2018-06-22 |
2021-06-29 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid-coated particles for treating viral infections
|
|
KR20210040943A
(ko)
|
2018-06-26 |
2021-04-14 |
매사추세츠 인스티튜트 오브 테크놀로지 |
Crispr 이펙터 시스템 기반 증폭 방법, 시스템, 및 진단
|
|
CN112368396A
(zh)
|
2018-06-26 |
2021-02-12 |
博德研究所 |
基于crispr/cas和转座酶的扩增组合物、系统和方法
|
|
US11629179B2
(en)
|
2018-06-29 |
2023-04-18 |
Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis |
TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
|
|
CA3104856A1
(en)
|
2018-06-29 |
2020-01-02 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
CN112513270B
(zh)
|
2018-07-13 |
2025-02-25 |
加利福尼亚大学董事会 |
基于逆转录转座子的递送媒介物及其使用方法
|
|
AU2019314433A1
(en)
|
2018-07-31 |
2021-03-25 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
JP2021532815A
(ja)
|
2018-08-07 |
2021-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Ｃａｓ１２ｂ酵素およびシステム
|
|
EP3833446A2
(en)
|
2018-08-10 |
2021-06-16 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
|
EP3607819A1
(en)
|
2018-08-10 |
2020-02-12 |
Vilmorin et Cie |
Resistance to xanthomonas campestris pv. campestris (xcc) in cauliflower
|
|
WO2020086144A2
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
|
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
EP3841205A4
(en)
|
2018-08-22 |
2022-08-17 |
The Regents of The University of California |
Variant type v crispr/cas effector polypeptides and methods of use thereof
|
|
JP7541508B2
(ja)
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス， インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
CN113286880A
(zh)
|
2018-08-28 |
2021-08-20 |
旗舰先锋创新Vi有限责任公司 |
调控基因组的方法和组合物
|
|
US11479762B1
(en)
|
2018-08-31 |
2022-10-25 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
EP3847650A1
(en)
|
2018-09-06 |
2021-07-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
|
CN112654702B
(zh)
|
2018-09-07 |
2025-05-13 |
阿斯利康(瑞典)有限公司 |
改进的核酸酶的组合物和方法
|
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
|
EP3852813A4
(en)
|
2018-09-18 |
2022-06-22 |
VNV Newco Inc. |
ARC-BASED CAPSIDS AND THEIR USES
|
|
WO2020061591A1
(en)
|
2018-09-21 |
2020-03-26 |
President And Fellows Of Harvard College |
Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins
|
|
US12252708B2
(en)
|
2018-09-24 |
2025-03-18 |
Unm Rainforest Innovations |
Living mammalian cells modified with functional modular nanoparticles
|
|
EP3868887A4
(en)
*
|
2018-09-25 |
2022-12-07 |
Microbial Chemistry Research Foundation |
NOVEL VIRAL VECTOR AND METHODS OF PRODUCTION AND USE THEREOF
|
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
WO2020082046A2
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor ix
|
|
WO2020081808A1
(en)
*
|
2018-10-18 |
2020-04-23 |
Chan Zuckerberg Biohub, Inc. |
Methods and compositions involving thermostable cas9 protein variants
|
|
US12116458B2
(en)
|
2018-10-24 |
2024-10-15 |
Genedit Inc. |
Cationic polymer with alkyl side chains and use for biomolecule delivery
|
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
WO2020092704A1
(en)
|
2018-10-31 |
2020-05-07 |
Zymergen Inc. |
Multiplexed deterministic assembly of dna libraries
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
|
|
PE20211292A1
(es)
|
2018-11-05 |
2021-07-20 |
Iovance Biotherapeutics Inc |
Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
|
|
WO2020096986A2
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
JP2022506508A
(ja)
|
2018-11-05 |
2022-01-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
|
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
|
US12460189B2
(en)
|
2018-11-09 |
2025-11-04 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US12402610B2
(en)
|
2018-11-09 |
2025-09-02 |
The Broad Institute, Inc. |
Methods and compositions for modulating innate lymphoid cell pathogenic effectors
|
|
US12165743B2
(en)
|
2018-11-09 |
2024-12-10 |
The Broad Institute, Inc. |
Compressed sensing for screening and tissue imaging
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
BR112021011372A2
(pt)
|
2018-12-14 |
2021-08-31 |
Pioneer Hi-Bred International, Inc. |
Novos sistemas crispr-cas para edição de genoma
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US12264323B2
(en)
|
2018-12-17 |
2025-04-01 |
The Broad Institute, Inc. |
CRISPR CPF1 direct repeat variants
|
|
CN113544266A
(zh)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
Crispr相关转座酶系统和其使用方法
|
|
CA3124039A1
(en)
|
2018-12-19 |
2020-06-25 |
King's College London |
Immunotherapeutic methods and compositions
|
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
IL312708A
(en)
*
|
2018-12-27 |
2024-07-01 |
Lifeedit Therapeutics Inc |
Polypeptides useful for gene editing and methods of use
|
|
JP2022517324A
(ja)
|
2019-01-03 |
2022-03-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
癌を患っている被験者における、ｃｄ８陽性ｔ細胞依存性免疫応答を増強させるための方法及び医薬組成物
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020160100A1
(en)
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
VARIANTS OF ADENINE DNA BASES WITH REDUCED OFF-TARGET RNA EDIT
|
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
|
US10982200B2
(en)
|
2019-02-14 |
2021-04-20 |
Metagenomi Ip Technologies, Llc |
Enzymes with RuvC domains
|
|
MX2021009886A
(es)
*
|
2019-02-14 |
2021-10-13 |
Metagenomi Inc |
Enzimas con dominios ruvc.
|
|
EP3924477A4
(en)
*
|
2019-02-14 |
2023-03-29 |
Metagenomi, Inc. |
ENZYMES WITH RUVC DOMAINS
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
US12208164B2
(en)
|
2019-02-28 |
2025-01-28 |
Unm Rainforest Innovations |
Modular metal-organic polyhedra superassembly compositions
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
WO2020181101A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
KR20210136997A
(ko)
|
2019-03-08 |
2021-11-17 |
지머젠 인코포레이티드 |
미생물에서 반복적 게놈 편집
|
|
CA3132840A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
|
KR20210143230A
(ko)
|
2019-03-19 |
2021-11-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
|
|
US20220162649A1
(en)
|
2019-04-01 |
2022-05-26 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
GB201905360D0
(en)
|
2019-04-16 |
2019-05-29 |
Univ Nottingham |
Fungal strains, production and uses thereof
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
KR20220005019A
(ko)
|
2019-04-23 |
2022-01-12 |
진에딧 인코포레이티드 |
알킬 곁사슬을 갖는 양이온성 폴리머
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
CA3139581A1
(en)
|
2019-05-03 |
2020-11-12 |
Specific Biologics Inc. |
Lipid-encapsulated dual-cleaving endonuclease for dna and gene editing
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CN114096684B
(zh)
|
2019-05-13 |
2024-11-19 |
科沃施种子欧洲股份两合公司 |
玉米的耐旱性
|
|
WO2020232138A1
(en)
|
2019-05-14 |
2020-11-19 |
Yield10 Bioscience, Inc. |
Modified plants comprising a polynucleotide comprising a non-cognate promoter operably linked to a coding sequence that encodes a transcription factor
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
US12509703B2
(en)
|
2019-05-21 |
2025-12-30 |
Sangamo Therapeutics, Inc. |
Controlled transgene expression in regulatory t cells
|
|
AR118995A1
(es)
|
2019-05-25 |
2021-11-17 |
Kws Saat Se & Co Kgaa |
Mejorador de la inducción de haploides
|
|
AU2020282798A1
(en)
|
2019-05-28 |
2021-12-16 |
Genedit Inc. |
Polymer comprising multiple functionalized sidechains for biomolecule delivery
|
|
BR112021021149A2
(pt)
|
2019-05-29 |
2021-12-14 |
Monsanto Technology Llc |
Métodos e composições para a geração de alelos dominantes utilizando a edição de genomas
|
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
|
WO2020244759A1
(en)
|
2019-06-05 |
2020-12-10 |
Klemm & Sohn Gmbh & Co. Kg |
New plants having a white foliage phenotype
|
|
WO2020254850A1
(en)
|
2019-06-21 |
2020-12-24 |
Vilmorin & Cie |
Improvement of quality and permanence of green color of peppers at maturity and over-maturity
|
|
JP2022539338A
(ja)
|
2019-06-25 |
2022-09-08 |
イナリ アグリカルチャー テクノロジー， インコーポレイテッド |
改良された相同性依存性修復ゲノム編集
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
WO2021009299A1
(en)
|
2019-07-17 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
|
|
WO2021019272A1
(en)
|
2019-07-31 |
2021-02-04 |
Vilmorin & Cie |
Tolerance to tolcndv in cucumber
|
|
EP4007595A4
(en)
*
|
2019-08-02 |
2023-09-27 |
Monsanto Technology LLC |
METHODS AND COMPOSITIONS FOR PROMOTING TARGETED GENOME CHANGES USING HUH ENDONUCLEASES
|
|
EP3772542A1
(en)
|
2019-08-07 |
2021-02-10 |
KWS SAAT SE & Co. KGaA |
Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
|
|
US20240175055A1
(en)
*
|
2019-08-08 |
2024-05-30 |
Fudan University |
Crispr/cas9 gene editing system and application thereof
|
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
AU2020345830A1
(en)
*
|
2019-09-09 |
2022-03-24 |
Beam Therapeutics Inc. |
Novel CRISPR enzymes, methods, systems and uses thereof
|
|
US20230025039A1
(en)
|
2019-09-20 |
2023-01-26 |
The Broad Institute, Inc. |
Novel type vi crispr enzymes and systems
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
US11987791B2
(en)
|
2019-09-23 |
2024-05-21 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
CN115175991A
(zh)
|
2019-10-16 |
2022-10-11 |
博德研究所 |
工程化肌肉靶向组合物
|
|
AU2020366566A1
(en)
|
2019-10-17 |
2022-04-21 |
KWS SAAT SE & Co. KGaA |
Enhanced disease resistance of crops by downregulation of repressor genes
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2021095013A1
(en)
*
|
2019-11-13 |
2021-05-20 |
Crispr Therapeutics Ag |
Manufacturing process for making t cells expressing chimeric antigen receptors
|
|
AU2020382017A1
(en)
*
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Methods of manufacturing CAR-T cells
|
|
EP4057802A1
(en)
|
2019-11-14 |
2022-09-21 |
Vilmorin & Cie |
Resistance to acidovorax valerianellae in corn salad
|
|
AU2020388387A1
(en)
|
2019-11-22 |
2022-06-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
JP2023504314A
(ja)
|
2019-12-02 |
2023-02-02 |
シェイプ セラピューティクス インコーポレイテッド |
治療的編集
|
|
WO2021118990A1
(en)
|
2019-12-11 |
2021-06-17 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
IL271656A
(en)
|
2019-12-22 |
2021-06-30 |
Yeda Res & Dev |
System and methods for identifying cells that have undergone genome editing
|
|
WO2021146222A1
(en)
|
2020-01-13 |
2021-07-22 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
|
US20230073449A1
(en)
|
2020-01-23 |
2023-03-09 |
The Children's Medical Center Corporation |
Stroma-free t cell differentiation from human pluripotent stem cells
|
|
EP4093863A4
(en)
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
CRISPR-CAS ENZYMES WITH ENHANCED ON-TARGET ACTIVITY
|
|
EP4093864A4
(en)
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
|
|
CN115023226A
(zh)
|
2020-01-29 |
2022-09-06 |
福宏治疗公司 |
化合物及其用途
|
|
EP3872190A1
(en)
|
2020-02-26 |
2021-09-01 |
Antibodies-Online GmbH |
A method of using cut&run or cut&tag to validate crispr-cas targeting
|
|
IL296095A
(en)
|
2020-03-04 |
2022-11-01 |
Flagship Pioneering Innovations Vi Llc |
Improved methods and compositions for genome modulation
|
|
AU2021234302A1
(en)
|
2020-03-11 |
2022-11-10 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
AU2021237790A1
(en)
|
2020-03-20 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human CD45RC and uses thereof
|
|
AU2021248800A1
(en)
|
2020-03-31 |
2022-10-13 |
Metagenomi, Inc. |
Class II, Type II CRISPR systems
|
|
US12057197B2
(en)
|
2020-04-03 |
2024-08-06 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
|
US11433121B1
(en)
|
2020-04-03 |
2022-09-06 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid composition for the delivery of therapeutic cargos
|
|
US20250263752A1
(en)
|
2020-04-21 |
2025-08-21 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
|
US20230165909A1
(en)
|
2020-04-21 |
2023-06-01 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
|
EP4138805A1
(en)
|
2020-04-23 |
2023-03-01 |
Genedit Inc. |
Polymer with cationic and hydrophobic side chains
|
|
WO2021215897A1
(ko)
*
|
2020-04-24 |
2021-10-28 |
기초과학연구원 |
Cas9 또는 cas9 변이체를 이용한 유전체 교정
|
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
BR112022022603A2
(pt)
|
2020-05-08 |
2023-01-17 |
Broad Inst Inc |
Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
|
|
US12383555B2
(en)
|
2020-05-20 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancers
|
|
CN116782762B
(zh)
|
2020-05-29 |
2024-11-19 |
科沃施种子欧洲股份两合公司 |
植物单倍体诱导
|
|
WO2021245435A1
(en)
|
2020-06-03 |
2021-12-09 |
Vilmorin & Cie |
Melon plants resistant to scab disease, aphids and powdery mildew
|
|
AU2021285274A1
(en)
|
2020-06-05 |
2023-02-02 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the TOBRFV
|
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
EP4192952A1
(en)
|
2020-08-10 |
2023-06-14 |
Novartis AG |
Treatments for retinal degenerative diseases
|
|
AU2021328478A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
MX2023002017A
(es)
|
2020-08-20 |
2023-04-28 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para ceacam.
|
|
AU2021329371A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
KR20230079203A
(ko)
|
2020-10-02 |
2023-06-05 |
빌모린 & 씨아이이 |
보관 기간이 연장된 멜론
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
EP4243608A1
(en)
|
2020-11-11 |
2023-09-20 |
Leibniz-Institut für Pflanzenbiochemie (IPB) |
Fusion protein for editing endogenous dna of a eukaryotic cell
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
EP4001429A1
(en)
|
2020-11-16 |
2022-05-25 |
Antibodies-Online GmbH |
Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
|
|
MX2023006612A
(es)
|
2020-12-03 |
2023-06-19 |
Vilmorin & Cie |
Plantas de tomate resistentes a tobrfv, tmv, tomv y tommv y genes de resistencia correspondientes.
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
MX2023007643A
(es)
|
2020-12-23 |
2023-09-04 |
Flagship Pioneering Innovations V Inc |
Ensamblaje in vitro de cápsides de anellovirus que encierran arn.
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
AU2022221606A1
(en)
|
2021-02-16 |
2023-08-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
GB202103131D0
(en)
|
2021-03-05 |
2021-04-21 |
Biosystems Tech Limited |
Method for preparation of research organisms
|
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
|
IL307298A
(en)
|
2021-03-31 |
2023-11-01 |
Entrada Therapeutics Inc |
Cell-penetrating circular peptides
|
|
WO2022208489A1
(en)
|
2021-04-02 |
2022-10-06 |
Vilmorin & Cie |
Semi-determinate or determinate growth habit trait in cucurbita
|
|
BR112023021665A2
(pt)
|
2021-04-19 |
2023-12-19 |
Iovance Biotherapeutics Inc |
Método para tratar um câncer, e, composição
|
|
KR20240004618A
(ko)
*
|
2021-04-30 |
2024-01-11 |
메타지노미, 인크. |
Ruvc 도메인을 갖는 효소
|
|
US20240374761A1
(en)
|
2021-05-05 |
2024-11-14 |
Radius Pharmaceuticals, Inc. |
Animal model having homologous recombination of mouse pth1 receptor
|
|
WO2022240760A2
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
|
|
US20240358845A1
(en)
|
2021-05-10 |
2024-10-31 |
Entrada Therapeutics, Inc. |
Compositions and methods for intracellular therapeutics
|
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
|
US20240102007A1
(en)
|
2021-06-01 |
2024-03-28 |
Arbor Biotechnologies, Inc. |
Gene editing systems comprising a crispr nuclease and uses thereof
|
|
EP4352131A1
(en)
|
2021-06-11 |
2024-04-17 |
Genedit Inc. |
Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups
|
|
IL309001A
(en)
|
2021-06-23 |
2024-02-01 |
Entrada Therapeutics Inc |
Antisense compounds and methods for targeting CUG repeats
|
|
US20240327859A1
(en)
*
|
2021-07-02 |
2024-10-03 |
University Of Maryland, College Park |
Cytidine deaminases and methods of genome editing using the same
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
|
US20240342285A1
(en)
|
2021-07-28 |
2024-10-17 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
CN118368974A
(zh)
|
2021-07-30 |
2024-07-19 |
科沃施种子欧洲股份两合公司 |
具有提高的消化率和标记单倍型的植物
|
|
MX2024001624A
(es)
|
2021-08-06 |
2024-04-30 |
Vilmorin & Cie |
Resistencia a leveillula taurica en el pimiento.
|
|
CN119452085A
(zh)
|
2021-08-27 |
2025-02-14 |
宏基因组学公司 |
具有ruvc结构域的酶
|
|
WO2023031885A1
(en)
|
2021-09-02 |
2023-03-09 |
SESVanderHave NV |
Methods and compositions for ppo herbicide tolerance
|
|
JP7125727B1
(ja)
|
2021-09-07 |
2022-08-25 |
国立大学法人千葉大学 |
核酸配列改変用組成物および核酸配列の標的部位を改変する方法
|
|
MX2024002927A
(es)
*
|
2021-09-08 |
2024-05-29 |
Flagship Pioneering Innovations Vi Llc |
Metodos y composiciones para modular un genoma.
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
KR20240099180A
(ko)
|
2021-09-20 |
2024-06-28 |
레비비코르 인코포레이션 |
이종이식을 위한 10개의 유전자 변형을 포함하는 다중전이유전자 돼지
|
|
US20240392272A1
(en)
|
2021-09-28 |
2024-11-28 |
Acrigen Biosciences |
Compositions and methods for nucleic acid modifications
|
|
EP4408996A2
(en)
|
2021-09-30 |
2024-08-07 |
Astrazeneca AB |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2023060132A1
(en)
*
|
2021-10-05 |
2023-04-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Allele specific editing to treat fus-induced neurodegeneration
|
|
WO2023059846A1
(en)
|
2021-10-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
EP4423755A2
(en)
|
2021-10-27 |
2024-09-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
US20250043269A1
(en)
|
2021-11-03 |
2025-02-06 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad |
Precise Genome Editing Using Retrons
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
WO2023085433A1
(ja)
|
2021-11-15 |
2023-05-19 |
国立大学法人鳥取大学 |
ヒト細胞内でヒト人工染色体ベクターを作製する方法
|
|
WO2023097282A1
(en)
|
2021-11-24 |
2023-06-01 |
Metagenomi, Inc. |
Endonuclease systems
|
|
US20240408236A1
(en)
|
2021-11-26 |
2024-12-12 |
Epigenic Therapeutics, Inc. |
Method of modulating pcsk9 and uses thereof
|
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
|
EP4453212A1
(en)
|
2021-12-23 |
2024-10-30 |
University of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4479143A1
(en)
|
2022-02-18 |
2024-12-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
|
EP4256950A1
(en)
|
2022-04-06 |
2023-10-11 |
Vilmorin et Cie |
Tolerance to cgmmv in cucumber
|
|
JP2025512313A
(ja)
|
2022-04-06 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
WO2023219933A1
(en)
|
2022-05-09 |
2023-11-16 |
Entrada Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acid therapeutics
|
|
EP4522210A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
US20250295810A1
(en)
|
2022-05-09 |
2025-09-25 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
JP2025516551A
(ja)
|
2022-05-10 |
2025-05-30 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｉｌ－１５ｒアゴニストと併用した腫瘍浸潤リンパ球療法によるがん患者の治療
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
KR20250019772A
(ko)
|
2022-05-25 |
2025-02-11 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
|
|
EP4532765A2
(en)
|
2022-05-25 |
2025-04-09 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulation of immune responses
|
|
EP4640849A2
(en)
|
2022-05-25 |
2025-10-29 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulating genetic drivers
|
|
KR20250017230A
(ko)
|
2022-05-25 |
2025-02-04 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
사이토카인을 조절하기 위한 조성물 및 방법
|
|
CA3254388A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
COMPOSITIONS AND METHODS OF MODULATING TRAFFIC FACTORS
|
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
CA3262406A1
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems and methods of use
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
WO2024023734A1
(en)
|
2022-07-26 |
2024-02-01 |
Bit Bio Limited |
MULTI-gRNA GENOME EDITING
|
|
WO2024030930A2
(en)
*
|
2022-08-01 |
2024-02-08 |
The Johns Hopkins University |
Compositions and methods for modifying muller glial cells
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250386788A1
(en)
|
2022-08-26 |
2025-12-25 |
KWS SAAT SE & Co. KGaA |
Use of paired genes in hybrid breeding
|
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
|
CA3265262A1
(en)
|
2022-09-01 |
2024-03-07 |
SESVanderHave NV |
PROCESSES AND COMPOSITIONS FOR HERBICIDE TOLERANCE PPO
|
|
WO2024050544A2
(en)
|
2022-09-01 |
2024-03-07 |
J.R. Simplot Company |
Enhanced targeted knock-in frequency in host genomes through crispr exonuclease processing
|
|
EP4583905A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
EP4598944A2
(en)
|
2022-10-03 |
2025-08-13 |
The Regents of the University of California |
Circumventing barriers to hybrid crops from genetically distant crosses
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
CN120584182A
(zh)
|
2022-11-21 |
2025-09-02 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞扩增的二维过程及其疗法
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
WO2024141599A1
(en)
|
2022-12-29 |
2024-07-04 |
Vilmorin & Cie |
Tomato plants resistant to resistance-breaking tswv strains and corresponding resistance genes
|
|
EP4658061A1
(en)
|
2023-02-01 |
2025-12-10 |
United Beet Seeds |
Beet yellows virus resistance
|
|
WO2024168265A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Aav delivery of rna guided recombination system
|
|
WO2024168253A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Delivery of an rna guided recombination system
|
|
CN120712355A
(zh)
|
2023-02-15 |
2025-09-26 |
阿伯生物技术公司 |
用于抑制抑微管装配蛋白2（stmn2）转录物中的异常剪接的基因编辑方法
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
US12225874B2
(en)
|
2023-03-27 |
2025-02-18 |
Redsea Science And Technology Inc. |
Tomato plant designated ‘X22-31’
|
|
CN121127605A
(zh)
|
2023-03-29 |
2025-12-12 |
阿斯利康(瑞典)有限公司 |
使用抑制剂来提高CRISPR/Cas插入的效率
|
|
WO2024211287A1
(en)
|
2023-04-03 |
2024-10-10 |
Seagen Inc. |
Production cell lines with targeted integration sites
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220741A1
(en)
|
2023-04-19 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for the production of libraries
|
|
WO2024218295A1
(en)
|
2023-04-21 |
2024-10-24 |
Vib Vzw |
Allelic combinations in crops for yield increase
|
|
CN121013646A
(zh)
|
2023-04-28 |
2025-11-25 |
维尔莫林公司 |
赋予改善的ToBRFV抗性的遗传决定子
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236547A1
(en)
|
2023-05-18 |
2024-11-21 |
Inceptor Bio, Llc |
Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
TW202509220A
(zh)
|
2023-06-26 |
2025-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
經工程化之瘧原蟲及相關方法
|
|
WO2025003305A1
(en)
|
2023-06-28 |
2025-01-02 |
Vilmorin & Cie |
Pepper resistance to meloidogyne enterolobii
|
|
WO2025021893A1
(en)
|
2023-07-24 |
2025-01-30 |
Vilmorin & Cie |
Resistance to cysdv in melons
|
|
US20250043304A1
(en)
|
2023-08-03 |
2025-02-06 |
J.R. Simplot Company |
Fusarium wilt resistance genes
|
|
WO2025046513A1
(en)
|
2023-08-29 |
2025-03-06 |
Inceptor Bio, Llc |
Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
WO2025059215A1
(en)
|
2023-09-12 |
2025-03-20 |
Aadigen, Llc |
Methods and compositions for treating or preventing cancer
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
GB202314578D0
(en)
|
2023-09-22 |
2023-11-08 |
Univ Manchester |
Methods of producing homoplasmic modified plants or parts thereof
|
|
EP4554371A1
(en)
|
2023-10-03 |
2025-05-21 |
Inari Agriculture Technology, Inc. |
Viral delivery of grna to the scion
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025111526A1
(en)
|
2023-11-22 |
2025-05-30 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025168705A1
(en)
|
2024-02-08 |
2025-08-14 |
Vib Vzw |
Means and methods for the production of saponins with endosomal escape-enhancing properties
|
|
WO2025171210A1
(en)
|
2024-02-09 |
2025-08-14 |
Arbor Biotechnologies, Inc. |
Compositions and methods for gene editing via homology-mediated end joining
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025186284A1
(en)
|
2024-03-05 |
2025-09-12 |
Vilmorin & Cie |
Increased yield in cucumber
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025240947A1
(en)
|
2024-05-17 |
2025-11-20 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
US20250382627A1
(en)
|
2024-06-13 |
2025-12-18 |
J.R. Simplot Company |
Engineering remontant flowering in rosaceae
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|